DE602005023334D1 - Isotopenmarkierte chinolinderivate als liganden des adenosin-a3-rezeptors - Google Patents

Isotopenmarkierte chinolinderivate als liganden des adenosin-a3-rezeptors

Info

Publication number
DE602005023334D1
DE602005023334D1 DE602005023334T DE602005023334T DE602005023334D1 DE 602005023334 D1 DE602005023334 D1 DE 602005023334D1 DE 602005023334 T DE602005023334 T DE 602005023334T DE 602005023334 T DE602005023334 T DE 602005023334T DE 602005023334 D1 DE602005023334 D1 DE 602005023334D1
Authority
DE
Germany
Prior art keywords
receptor
isotopenmarked
adenosine
ligands
chinoline derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005023334T
Other languages
English (en)
Inventor
Geza Timari
Kinga Boer
Geza Toth
Csaba Toemboely
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of DE602005023334D1 publication Critical patent/DE602005023334D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • C07D215/28Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22Tin compounds
    • C07F7/2208Compounds having tin linked only to carbon, hydrogen and/or halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
DE602005023334T 2004-11-15 2005-11-09 Isotopenmarkierte chinolinderivate als liganden des adenosin-a3-rezeptors Active DE602005023334D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0402371A HUP0402371A2 (en) 2004-11-15 2004-11-15 Novel 125-i-labeled amino-quinoline derivatives
PCT/HU2005/000120 WO2006051341A1 (en) 2004-11-15 2005-11-09 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands

Publications (1)

Publication Number Publication Date
DE602005023334D1 true DE602005023334D1 (de) 2010-10-14

Family

ID=89985606

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005023334T Active DE602005023334D1 (de) 2004-11-15 2005-11-09 Isotopenmarkierte chinolinderivate als liganden des adenosin-a3-rezeptors

Country Status (15)

Country Link
US (1) US7964731B2 (de)
EP (1) EP1814857B1 (de)
JP (1) JP2008519816A (de)
KR (1) KR20070084202A (de)
CN (1) CN101056859B (de)
AT (1) ATE479660T1 (de)
AU (1) AU2005303544B2 (de)
BR (1) BRPI0517816A (de)
CA (1) CA2588073A1 (de)
DE (1) DE602005023334D1 (de)
HU (1) HUP0402371A2 (de)
IL (1) IL182971A0 (de)
MX (1) MX2007005768A (de)
RU (1) RU2379290C2 (de)
WO (1) WO2006051341A1 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
RU2278112C2 (ru) * 2001-05-31 2006-06-20 Санофи-Авентис Производные аминохинолина и аминопиридина и их применение в качестве лигандов аденозина a3

Also Published As

Publication number Publication date
WO2006051341A1 (en) 2006-05-18
CN101056859A (zh) 2007-10-17
HUP0402371A2 (en) 2006-09-28
RU2379290C2 (ru) 2010-01-20
RU2007122396A (ru) 2008-12-20
JP2008519816A (ja) 2008-06-12
CN101056859B (zh) 2010-05-05
MX2007005768A (es) 2007-07-16
US7964731B2 (en) 2011-06-21
EP1814857B1 (de) 2010-09-01
EP1814857A1 (de) 2007-08-08
BRPI0517816A (pt) 2008-10-21
AU2005303544B2 (en) 2011-06-02
CA2588073A1 (en) 2006-05-18
ATE479660T1 (de) 2010-09-15
HU0402371D0 (en) 2005-03-29
IL182971A0 (en) 2007-08-19
AU2005303544A1 (en) 2006-05-18
KR20070084202A (ko) 2007-08-24
US20080027225A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
HRP20090235A2 (en) Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands
MY143834A (en) Thrombin receptor antagonists
DE502006006854D1 (de) Substituierte benzo (d) isoaxol-3-yl-amin-verbindungen als analgetika
HRP20040618B1 (hr) Supstituirani 2-tio-3,5-dicijano-4-fenil-6-aminopiridini i njihova upotreba
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
ATE384039T1 (de) Indanderivate als muscarinrezeptoragonisten
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт
JO2689B1 (en) New vehicles
RS56004A (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands
ATE461172T1 (de) Azetidinderivate als antagonisten des muskarinrezeptors
EA200970426A1 (ru) Селективный агонист tr-бета 1
DE602005023334D1 (de) Isotopenmarkierte chinolinderivate als liganden des adenosin-a3-rezeptors
WO2007034254A8 (en) Amino-alkyl-amide derivatives as ccr3 receptor ligands
BRPI0620694A2 (pt) composto, composição farmacêutica, processo para a preparação do composto, método para o tratamento de doenças inflamatórias mediado pela ativação de p38 map quinase e uso do composto
UA89846C2 (ru) Производные карбоксамида как антагонисты мускариновых рецепторов
CY1106649T1 (el) Νεα 1-μεθοξυ-2-φαινυλ-αιθενια χρησιμα δια την παρασκευην 5-καρβοξαλδεϋδο-2,3-διϋδροβενζοξεπινων
MX2007012608A (es) Derivados de 1[(5-r1-tiofen-; furan)-2-il-metilen]-2-[(r2)fenil] hidrazona, su metodo de obtencion y su uso para la preparacion de medicamentos para el mal de chagas.
MEP18808A (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands